Displaying 176 - 180 of 206
Wed 23 January 2013
Further details of a 2012 study have shown patients who received Abraxane in combination with the chemotherapy agent gemcitabine had an overall survival of 8.5 months.Read More about 'Cancer drug extends survival by nearly two months'
Mon 12 November 2012
In a Phase III study, Celgene's ABRAXANE® (NAB-PACLITAXEL), currently approved for breast and lung cancer, has been found to improve overall survival for patients with advanced pancreatic cancer.Read More about 'Cancer drug extends survival in patients with advanced pancreatic cancer'
Sun 11 November 2012
Clovis Oncology has announced the results from its LEAP study of CO-101 versus gemcitabine in metastatic pancreatic cancer.Read More about 'Negative outcome of pancreatic cancer study announced'
Tue 23 October 2012
Pancreatic Cancer UK is appealing to the public to raise their involvement in November's Pancreatic Cancer Awareness Month (PCAM), by taking part in its 'Raise for Research' campaign.Read More about 'Raise your voice (and funds) in aid of pancreatic cancer awareness month'
Mon 08 October 2012
National charity Pancreatic Cancer UK, which provides free patient information to health professionals, has launched two new information resources on surgery to mark Pancreatic Cancer Awareness Month in November.Read More about 'New information resources for pancreatic cancer patients launched'